| 3.69 0.075 (2.07%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.67 | 1-year : | 5.18 |
| Resists | First : | 4 | Second : | 4.44 |
| Pivot price | 3.87 |
|||
| Supports | First : | 3.29 | Second : | 2.74 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 3.78 |
| MA(100) : | 3.26 |
MA(250) : | 2.92 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 21 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 5 | Low : | 0.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIMD ] has closed above bottom band by 26.7%. Bollinger Bands are 20.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.72 - 3.73 | 3.73 - 3.75 |
| Low: | 3.57 - 3.59 | 3.59 - 3.61 |
| Close: | 3.66 - 3.69 | 3.69 - 3.72 |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Mon, 20 Oct 2025
$60B Edge AI Market: Ainos & NEXCOM Partner to Bring AI Nose to Industrial Edge in 2026 - Stock Titan
Tue, 14 Oct 2025
AI Nose integrated into NEXCOM edge platforms — Ainos expands SmellTech-as-a-Service worldwide - Stock Titan
Tue, 07 Oct 2025
123 Patents: Ainos Reclassified to Technology, Secures $2.1M Order; Expands IP & Robotics Pilots - Stock Titan
Tue, 07 Oct 2025
Water Tower Research Highlights Ainos' Transition to Technology Company Following GICS Reclassification - The Globe and Mail
Mon, 06 Oct 2025
Taiwan carbon nano technology sells Ainos (AIMD) shares for $7,170 - Investing.com
Fri, 29 Aug 2025
Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of Debt - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.43e+006 (%) |
| Held by Institutions | 56.4 (%) |
| Shares Short | 121 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.81e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -80 % |
| Return on Assets (ttm) | 327.8 % |
| Return on Equity (ttm) | -30.7 % |
| Qtrly Rev. Growth | 110870 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -43.09 |
| EBITDA (p.s.) | 40189.4 |
| Qtrly Earnings Growth | -4.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 3.12 |
| Dividend | 0 |
| Forward Dividend | 23160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|